Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Detection of Numerical Abnormalities of Chromosome 9 and p16/CDKN2A Gene Alterations in Ovarian Cancer with Fish Analysis

CHRISTOS ARAVIDIS, ANNA D. PANANI, ZOI KOSMAIDOU, NIKOLAOS THOMAKOS, ALEXANDROS RODOLAKIS and ARISTEIDIS ANTSAKLIS
Anticancer Research December 2012, 32 (12) 5309-5313;
CHRISTOS ARAVIDIS
1Critical Care Department, Cytogenetics Unit, Evangelismos Hospital, Medical School of Athens University, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: christos.aravidis@yahoo.gr
ANNA D. PANANI
1Critical Care Department, Cytogenetics Unit, Evangelismos Hospital, Medical School of Athens University, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ZOI KOSMAIDOU
2Department of Genetics, Alexandra Hospital, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NIKOLAOS THOMAKOS
3Department of Obstetrics and Gynecology, Alexandra Hospital, Medical School of Athens University, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALEXANDROS RODOLAKIS
3Department of Obstetrics and Gynecology, Alexandra Hospital, Medical School of Athens University, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ARISTEIDIS ANTSAKLIS
3Department of Obstetrics and Gynecology, Alexandra Hospital, Medical School of Athens University, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: The molecular events leading to the development of ovarian cancer are not well-established. Defects of the retinoblastoma protein (pRb)/cyclin-D1/p16 pathway have been shown to play a critical role in the development of human malignancies. In particular, the p16/cyclin-dependent kinase inhibitor 2A (CDKN2A) gene located on chromosomal region 9p21 frequently is altered in several types of cancer. Materials and Methods: To investigate both the presence of numerical abnormalities of chromosome 9 and p16 gene alterations in ovarian cancer, we studied 28 cases by the fluorescence in situ hybridization (FISH) technique using a DNA p16 probe and an a-satellite probe specific for chromosome 9. Results: Numerical abnormalities of chromosome 9 were found in all studied cases. Polysomy 9 was detected in 10 cases while monosomy 9 in seven cases. In 11 cases, there were two cell populations, one with polysomy 9 and the other with monosomy 9. In all cases, the p16 gene deletion was observed. Among them, 25 cases presented deletion of p16 gene in 21.43%-86.3% of the examined cells. Three cases carried deletion of the p16 gene in a lower proportion (12.04%-19.49%). In five cases with p16 gene deletion, homozygous deletion was detected. Conclusion: Numerical aberrations of chromosome 9 and p16 gene deletion are common findings in ovarian cancer. Data suggest that the p16 gene, located in the short arms of chromosome 9, may play a role in ovarian carcinogenesis. In addition, polysomy 9 could lead to activation of a number of oncogenes, thus participating in the neoplastic process in the ovaries.

  • Ovarian cancer
  • genetic changes
  • chromosome 9 numerical abnormalities
  • p16CDKN2A gene deletion
  • FISH technique

Ovarian cancer is one of the leading causes of death from gynaecological malignancies worldwide. The molecular events leading to the development of ovarian cancer and the molecular factors that may predict response to treatment are not well-established. De-regulation of cell-cycle control, in particular G1- to S-phase transition, is implicated in the pathogenesis of most types of human cancer, including ovarian cancer (1). The tumor suppressor gene p16/cyclin-dependent kinase inhibitor-2A (CDKN2A) is located within the chromosomal region 9p21 and encodes a cell-cycle protein that is an inhibitor of cyclin-dependent kinases (CDK)-4 and -6. As a result, it negatively regulates cyclin-D-dependent phosphorylation of the retinoblastoma (pRb) gene product, thus blocking cell-cycle progression from G1-to S-phase (2-4). Loss of function of the p16 gene has been reported to occur mainly by homozygous deletion, mutation or aberrant DNA methylation of the promoter of the region (5-8).

A number of studies have shown that p16/CDKN2A is frequently altered in melanoma (9), pancreatic (10), urinary bladder (11) and lung cancer (12). There are few studies focusing on the molecular analysis of p16 gene in ovarian cancer (13-16). The aim of the present study was to determine the significance of this tumor suppressor gene for ovarian tumorigenesis, investigating both numerical aberrations of chromosome 9 and p16 gene alterations in 28 cases of ovarian tumors, by the fluorescence in situ hybridization (FISH) technique.

Materials and Methods

Twenty-eight cases of patients who had undergone surgical resection of ovarian cancer between the years 2005 to 2009 were included in the present study. Among the methods used for cytogenetic evaluation was the FISH technique for p16 gene deletion. Tissue specimens were collected from fresh surgically resected tumors in 27 cases and in one case, ascitic effusion was taken just before a surgery with fine-needle aspiration biopsy (FNA). None of the patients had ever received chemotherapy or radiation prior to surgery. The FISH technique was applied to recently made slides from methanol/acetic acid-fixed cells using a DNA p16 probe and an α-satellite probe specific for chromosome 9. The p16 probe, (Cytocell Ltd., Cambridge, UK), labeled red, covered a 101-kb region of 9p21 extending from 59 kb 3’ of p16 to the 5’ end of p15. The probe mix also contained a control probe for chromosome 9 (D9Z3, the heterochromatic block at 9q12 region), labeled green. The technique was carried out according to the manufacturer's instructions. The hybridization was visualized by fluorescence microscope, equipped with selective filters for the fluorochromes used.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Numerical aberrations of chromosome 9 and p16 gene alterations in 28 cases of ovarian cancer.

As far as the evaluation of the signal is concerned, a normal cell has two copies of chromosome 9 (two green spots) and two copies of p16 gene (two red spots). Cells with deletion of p16 gene have fewer red spots than green. Cells with one red and one green spot have deletion of p16 gene and monosomy 9. A minimum of 150 non-overlapping cells from each slide were evaluated for each case. Signals were scored using well-established criteria (17). To avoid misinterpretation due to technical error, normal lymphocyte nuclei were used as a control. A case was defined as abnormal if more than 10% of cells showed losses or gains of signals for chromosome 9 and the p16 gene. The present study was approved by the local Ethical Committee.

Results

Results are shown in Table I. Numerical abnormalities of chromosome 9 were found in all studied cases. Polysomy 9 was detected in 10 cases, while monosomy 9 in seven cases. In 11 cases, there were two cell populations, one with polysomy 9 and the other with monosomy 9. In the entire case cohort, p16 gene deletion was observed (red spots<green spots) (Figure 1). Among them, 25 cases presented deletion of the p16 gene in 21.43%-86.3% of the examined cells. Three cases carried deletion of p16 gene in a lower proportion, between 12.04%-19.49% of the examined cells. In five cases with p16 gene deletion, the gene was deleted homozygously in 12.88%, 13.74%, 15.44%, 55.34% and 60.58% of the examined cells, respectively. Moreover, in 14 cases, there was a cell population with one copy of chromosome 9 and one p16 gene (one red and one green spot) in 10.17%-40.38% of cells. Finally, in 12 cases, a cell population with p16 gains equal to chromosome 9 copies (red spots=green spots, >2), was found for 10.61 to 61.73% of the examined cells.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Copy number of chromosome 9 (green spots) and p16 gene (red spots) detected by fluorescence in situ hybridization (FISH) in ovarian cancer cells from different cases. Cells with one copy (top left image) and two copies (top center) of chromosome 9 and absence of p16 gene. Cell with two chromosomes 9 and only one copy of p16 (top right). Four chromosomes 9 and only one copy of p16 gene (middle left), three copies of chromosome 9 and two p16 gene copies (middle center image) three chromosomes 9 and three copies of p16 (middle right). Multiple copies of chromosome 9 and p16 gene copies (bottom images).

Discussion

Several studies have investigated the genetic changes in ovarian carcinogenesis, in order to identify specific molecular markers, which provide information regarding prognosis and also the development of new therapeutic strategies. Molecular studies focusing on tumor suppressor gene p16 showed that its inactivation has an important role in carcinogenesis of several types (9-12). The inactivation of p16 gene is mainly caused by homozygous deletion, mutations or promoter hypermethylation of the gene.

There are a number of studies focused on the p16 gene alteration in ovarian tumorigenesis, most of which are based on polymerase chain reaction (PCR) analysis techniques and immunohistochemistry for protein expression (18-23). Nevertheless, results from these studies provided conflicting information concerning the expression of the gene, and the prognostic significance of differential expression levels of cell-cycle regulatory protein-product in ovarian carcinomas. This may be a result either of the size of the samples used for this technique or broad heterogeneity of the patients with respect to stage and postoperative therapy. However, one large-scale prospective study of advanced-stage ovarian cancer indicated that p16-positive tumors have better survival rate compared to p16-negative tumors (24).

In our study, we utilized FISH to determine numerical abnormalities of chromosome 9 and p16 gene alterations in ovarian cancer. Interestingly, all ovarian cancer cases, regardless of histological subtype, tumour stage or grade, exhibited p16 gene deletion in a range of proportion from 12.04% to 86.3% of the examined cells. Moreover, numerical aberrations of chromosome 9 were present in every case. Polysomy 9 was detected in 10 cases, while monosomy 9 in seven cases. In 11 cases, two cell populations were found, one with monosomy and one with polysomy 9. Our data show that numerical aberrations of chromosome 9 and p16 gene deletion are common findings in all subtypes of ovarian cancer. It seems evident that in cases with one red and one green spot, loss of p16 gene is due to chromosome 9 monosomy. Similarly, in cases with gains of p16 gene copies equal to those of chromosome 9, the gene copies result from chromosome 9 polysomy.

The FISH technique is considered the most reliable method for detecting homozygous gene deletions. In five of our cases with p16 gene deletion, the gene was deleted homozygously in 12.88%-60.58% of the examined cells. High frequency of homozygous deletion of p16 gene has been reported in cell lines from several cancer types (25). Moreover, studies showed that homozygous deletion of the p16 gene is a common finding in ovarian cancer cell lines (8, 26). However, regarding primary ovarian cancer cells, homozygous deletion of p16 gene is not a recurrent finding, thus in one study, the gene was homozygously deleted at a very low frequency (1/67 cases) (6). It should be noted that the evaluation of these findings depends on the technique applied for the analysis (PCR, loss of heterozygosity-LOH, representative DNA analysis-RDA).

Besides p16 gene inactivation, novel data based on techniques of RDA identify alternate pathways for tumorigenesis. It is suggested that genes such as IFN-α, p16, p15 and other unknown tumor suppressor genes, which could be implicated in ovarian carcinogenesis, are located in the chromosomal region 9p21 (27). Additionally, data of the present study may indicate that a number of oncogenes, in association with polysomy 9, could contribute to ovarian carcinogenesis.

Moreover, our study suggests that there might not be a correlation between genetic changes and of particular histological subtypes, stage or grade of this neoplastic disease. Hence, the fact that similar recurring genetic aberrations have been observed within different histological subtypes of ovarian cancer might suggest that there are no tissue-specific differences in the genetic changes by which neoplasia is initiated or progresses. However, in order to verify and establish this, more data from cytogenetic studies are required.

In conclusion, the FISH technique using cocktail probes specific for chromosome 9 and the p16 gene is a valuable method for concurrently detecting numerical abnormalities of chromosome 9 and numerical alterations of p16 gene copies, events which are common findings in ovarian cancer. The utilization of molecular technologies that allow for high throughput analysis of genes has provided new insights into gene expression profiles in ovarian cancer and may lead to the development of new biomarkers or novel therapies for this neoplasia.

  • Received September 26, 2012.
  • Revision received October 26, 2012.
  • Accepted October 29, 2012.
  • Copyright© 2012 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Wang N
    : Cytogenetics and molecular genetics of ovarian cancer. Am J Med Genet 115: 157-163, 2002.
    OpenUrlPubMed
  2. ↵
    1. Serrano M,
    2. Hannon GJ,
    3. Beach D
    : A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366(6456): 704-707, 1993.
    OpenUrlCrossRefPubMed
    1. Fåhraeus R,
    2. Ball K,
    3. Laín S,
    4. Lane D,
    5. David P
    : Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr Biol 6(1): 84-91, 1996.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Russo A,
    2. Lee J,
    3. Jeffrey P,
    4. Pavletich N,
    5. Jeffrey,
    6. Philip D
    : Structural basis for inhibition of the cyclin-dependent kinase CDK6 by the tumour suppressor p16INK4a Nature 395(6699): 237-243, 1998.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Cairns P,
    2. Polascik TJ,
    3. Eby Y,
    4. Tokino K,
    5. Califano J,
    6. Merlo A,
    7. Mao L,
    8. Herath J,
    9. Jenkins R,
    10. Westra W,
    11. Rutter JL,
    12. Buckler A,
    13. Gabrielson E,
    14. Tockman M,
    15. Cho KR,
    16. Hedrick L,
    17. Bova GS,
    18. Isaacs W,
    19. Koch W,
    20. Schwab D,
    21. Sidransky D
    : Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11: 210-212, 1995.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Campbell G,
    2. Beynon G,
    3. Davis M,
    4. Englefield P
    : LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int J Cancer 63: 222-225, 1995.
    OpenUrlPubMed
    1. Herman J,
    2. Merlo A,
    3. Mao L,
    4. Lapidus RG,
    5. Issa JP,
    6. Davidson N,
    7. Sidransky D,
    8. Baylin S
    : Inactivation of the CDKN2/p16/MTSJ gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530, 1995.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Shih C,
    2. Kerr J,
    3. Liu J,
    4. Hurst T,
    5. Khoo K,
    6. Ward B,
    7. Wainwright B,
    8. Chenevix-Trench G
    : Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours. Int J Cancer 70: 508-511, 1997.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Puig S,
    2. Ruiz A,
    3. Lazaro C,
    4. Castel T,
    5. Lynch M,
    6. Palou J,
    7. Vilalta A,
    8. Weissenbach J,
    9. Mascaro JM,
    10. Estivill X
    : Chromosome 9p deletions in cutaneous malignant melanoma tumors: The minimal deleted region involves markers outside the p16 (CDKN2) gene. Am J Hum Genet 57: 395-402, 1995.
    OpenUrlPubMed
  8. ↵
    1. Caldas C,
    2. Hahn SA,
    3. da Costa LT,
    4. Redston MS,
    5. Schutte M,
    6. Seymour AB,
    7. Weinstein CL,
    8. Hruban RH,
    9. Yeo CJ,
    10. Kern SE
    : Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8: 27-32, 1994.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Williamson P,
    2. Elder A,
    3. Shaw E,
    4. Devlin J,
    5. Knowles MA
    : p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 4: 1569-1577, 1995.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Panani AD,
    2. Maliaga K,
    3. Babanaraki A,
    4. Bellenis I
    : Numerical abnormalities of chromosome 9 and p16CDKN2A gene deletion detected by FISH in non-small cell lung cancer. Anticancer Res 29: 4483-4487, 2009.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Barbieri F,
    2. Cagnoli M,
    3. Ragni N,
    4. Foglia G,
    5. Bruzzo C,
    6. Pedullà F,
    7. Alama A
    : Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. Clin Cancer Res 5: 1837-1842, 1999.
    OpenUrlAbstract/FREE Full Text
    1. Dhar KK,
    2. Branigan K,
    3. Parkes J,
    4. Howells RE,
    5. Hand P,
    6. Musgrove C,
    7. Strange RC,
    8. Fryer AA,
    9. Redman CW,
    10. Hoban PR
    : Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells. Br J Cancer 81: 1174-1181, 1999.
    OpenUrlCrossRefPubMed
    1. Todd MC,
    2. Sclafani RA,
    3. Langan TA
    : Ovarian cancer cells that coexpress endogenous Rb and p16 are insensitive to overexpression of functional p16 protein. Oncogene 19: 258-264, 2000.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Rosenberg E,
    2. Demopoulos RI,
    3. Zeleniuch-Jacquotte A,
    4. Yee H,
    5. Sorich J,
    6. Speyer JL,
    7. Newcomb EW
    : Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. Hum Pathol 32: 808-813, 2001.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Hopman AH,
    2. Ramaekers FCS,
    3. Raap AK,
    4. Beck JLM,
    5. Devilee P,
    6. Ploeg M,
    7. Vooijs GP
    : In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry 89: 307-316, 1988.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Dong Y,
    2. Walsh MD,
    3. McGuckin MA,
    4. Gabrielli BG,
    5. Cummings MC,
    6. Wright RG,
    7. Hurst T,
    8. Khoo SK,
    9. Parsons PG
    : Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product p16INK4a in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer 74: 57-63, 1997.
    OpenUrlCrossRefPubMed
    1. Kusume T,
    2. Tsuda H,
    3. Kawabata M,
    4. Inoue T,
    5. Umesaki N,
    6. Suzuki T,
    7. Yamamoto K
    : The p16–cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin Cancer Res 5: 4152-4157, 1999.
    OpenUrlAbstract/FREE Full Text
    1. Sui L,
    2. Dong Y,
    3. Ohno M,
    4. Goto M,
    5. Inohara T,
    6. Sugimoto K,
    7. Tai Y,
    8. Hando T,
    9. Tokuda M
    : Inverse expression of Cdk4 and p16 in epithelial ovarian tumors. Gynecol Oncol 79: 230-237, 2000.
    OpenUrlCrossRefPubMed
    1. Milde-Langosch K,
    2. Hagen M,
    3. Bamberger AM,
    4. Loning T
    : Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p17KIP1, cyclin E, and cyclin D2, in ovarian cancer. Int J Gynecol Pathol 22: 168-174, 2003.
    OpenUrlCrossRefPubMed
    1. Raspollini MR,
    2. Amunni G,
    3. Villanucci A,
    4. Baroni G,
    5. Taddei GL
    : p16INK4a overexpression is associated with poor clinical outcome in ovarian cancer. J Chemother 16: 411-413, 2004.
    OpenUrlPubMed
  15. ↵
    1. Hashiguchi Y,
    2. Tsuda H,
    3. Inoue T,
    4. Nishimura S,
    5. Suzuki T,
    6. Kawamura N
    : Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients. Hum Pathol 35: 165-175, 2004.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Kommoss S,
    2. du Bois A,
    3. Ridder R,
    4. Trunk MJ,
    5. Schmidt D,
    6. Pfisterer J,
    7. Kommoss F
    . Independent prognostic significance of cell cycle regulator proteins p16INK4a and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Br J Cancer 96: 306-313, 2007.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Nobori T,
    2. Miura K,
    3. Wu DJ,
    4. Lois A,
    5. Takabayashi K,
    6. Carson DA
    : Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756, 1994.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Rodabaugh KJ,
    2. Biggs RB,
    3. Qureshi JA,
    4. Barrett AJ,
    5. Welch WR,
    6. Bell DA,
    7. Berkowitz RS,
    8. Mok SC
    : Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors. Oncogene 11: 1249-1254, 1995.
    OpenUrlPubMed
  19. ↵
    1. Watson JE,
    2. Gabra H,
    3. Taylor KJ,
    4. Rabiasz GJ,
    5. Morrison H,
    6. Perry P,
    7. Smyth JF,
    8. Porteous DJ
    : Identification and characterization of a homozygous deletion found in ovarian ascites by representational difference analysis. Genome Res 9: 226-233, 2009.
    OpenUrl
PreviousNext
Back to top

In this issue

Anticancer Research: 32 (12)
Anticancer Research
Vol. 32, Issue 12
December 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Detection of Numerical Abnormalities of Chromosome 9 and p16/CDKN2A Gene Alterations in Ovarian Cancer with Fish Analysis
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Detection of Numerical Abnormalities of Chromosome 9 and p16/CDKN2A Gene Alterations in Ovarian Cancer with Fish Analysis
CHRISTOS ARAVIDIS, ANNA D. PANANI, ZOI KOSMAIDOU, NIKOLAOS THOMAKOS, ALEXANDROS RODOLAKIS, ARISTEIDIS ANTSAKLIS
Anticancer Research Dec 2012, 32 (12) 5309-5313;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Detection of Numerical Abnormalities of Chromosome 9 and p16/CDKN2A Gene Alterations in Ovarian Cancer with Fish Analysis
CHRISTOS ARAVIDIS, ANNA D. PANANI, ZOI KOSMAIDOU, NIKOLAOS THOMAKOS, ALEXANDROS RODOLAKIS, ARISTEIDIS ANTSAKLIS
Anticancer Research Dec 2012, 32 (12) 5309-5313;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Long Noncoding RNA ANRIL Regulates Proliferation of Non-small Cell Lung Cancer and Cervical Cancer Cells
  • Transcriptional Regulation of the p16 Tumor Suppressor Gene
  • Google Scholar

More in this TOC Section

  • 5-Azacytidine (5-aza) Induces p53-associated Cell Death Through Inhibition of DNA Methyltransferase Activity in Hep3B and HT-29 Cells
  • Prognostic Value of WNT1, NOTCH1, PDGFRβ, and CXCR4 in Oral Squamous Cell Carcinoma
  • Hypoxia-adapted Multiple Myeloma Stem Cells Resist γδ-T-Cell-mediated Killing by Modulating the Mevalonate Pathway
Show more Experimental Studies

Similar Articles

Keywords

  • Ovarian cancer
  • genetic changes
  • chromosome 9 numerical abnormalities
  • p16CDKN2A gene deletion
  • FISH technique
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire